On January 26, 2026, the Company closed the third and final tranche of the non-brokered private placement and issued 352,174 shares for total proceeds of $810,000 to a company to which a member of the board of directors is related

On January 20, 2026, the Company received board approval, to open a non-brokered private placement of up to $5,000,000, offering shares at a price of $4.00 per share.  On March 23, 2026, the Company closed the non-brokered private placement and issued 486,970 shares at a price of $4.00 per share for total proceeds of $1,947,880.  The Company incurred $9,828 of offering costs in connection with this non-brokered private placement.

Private Placements - Brokered

On July 31, 2025, the Company filed with the Securities and Exchange Commission ("SEC") a Regulation Crowdfunding ("Reg CF") to raise up to $5,000,000 at a price of $2.00 per common share of the Company.

On September 2, 2025, the first tranche of the raise was closed with total gross proceeds of $2,726,303, representing a commitment of the Company to issue 1,363,151 common shares.  After associated fees and costs of $278,364, the net amount of $2,447,938 was advanced to the Company.

On September 18, 2025, a second tranche of the raise was closed with total gross proceeds of $1,969,970, representing a commitment of the Company to issue 984,985 common shares.  After associated fees and costs of $200,100, the net amount of $1,769,860 was advanced to the Company.

On October 7, 2025, the third and final tranche of the raise was closed with total gross proceeds of $303,652, representing a commitment of the Company to issue 151,826 common shares.  After associated fees and costs of $31,299, the net amount of $272,353 was advanced to the Company.  With the close of this final tranche, the Company issued a total of 2,499,962 common shares with total gross proceeds equaling $4,999,925 less total issuance costs of $509,773 for a net amount received of $4,490,152.

In connection with these raises the Company also issued 49,999 shares of common stock to the broker with a fair value of $99,998.

The fair value of the warrants issued in the private placements during the nine months ended July 31, 2026, and the year ended October 31, 2025, was determined using the following Black-Scholes Pricing model assumptions:

Shares Issued for Services

On May 8, 2025, the Company entered into a service agreement in which it was agreed that the consultant would provide advisory and consultancy services related to the Company's Form C disclosure documents required for a planned Regulation Crowdfunding ("Reg CF") offering, advising the Company on marketing, organizational and financial issues and business development.  The agreement was for a twelve (12) month period from its effective date of May 8, 2025, and includes a one-time cash payment of $75,000 as a retainer to be expensed monthly over the term of the agreement and is included in the consulting expense on the unaudited condensed interim statements of operations.  As of October 31, 2025, a balance of $37,500 remained outstanding and was included in the prepaid expenses on the condensed balance sheets. In addition to performing the defined services, the vendor was to make a one-time purchase of 1,200,000 shares of the Company's common stock at a price of $0.001 per share for gross proceeds of $1,200 which is accounted for as a reduction of the fair value of the shares issued.  The fair value of the shares was determined to be $480,000, which, net of the $1,200, is to be expensed over the term of the agreement. As of October 31, 2025, $247,927 was included in prepaid expenses on the condensed balance sheet.  During the three and nine months ended July 31, 2026, a total of $9,206 and $247,926, respectively, was expensed as consulting fees on the unaudited condensed interim statements of operations. During the three and nine months ended July 31, 2025, a total of $110,190 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.

On June 27, 2025, the Company granted 150,000 Restricted Share Units ("RSUs") to an advisor, having a fair value of $121,091.  The RSUs vested immediately and were expensed as consulting expense.  The RSUs may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated, other than under specific circumstances as defined in the Restricted Share Unit Awards Agreement.

On January 15, 2025, Director 1 received 82,500 shares of common stock for a fair value of $66,000 as disclosed in Note 10 - Related Party Transactions.  The stock vested immediately and $66,000 was expensed and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.

In May 2025, the Company also issued 416,667 shares of common stock to a consultant for a fair value of $166,667, which was expensed over the 24-month term of the agreement. As of October 31, 2025, $126,484 is included in prepaid expenses in the condensed balance sheets. On May 27, 2026, the Company mutually agreed to terminate, without penalty this consulting agreement and therefore during the three and nine months ended July 31, 2026, a total of $84,931 and $126,484 was expensed as consulting fees on the unaudited condensed interim statements of operations. During the three and nine months ended July 31, 2025, a total of $19,178, was recognized and was expensed as consulting fees on the unaudited condensed interim statements of operations. As of July 31, 2026, there was no longer any prepaid balance to be expensed.

On October 15, 2025, the Company also issued 442,514 shares of common stock to employees and a director of the Company as part of their employment and board of director's agreements with a fair value of $885,028.  The terms of these agreements were indefinite and the shares vested immediately.

On March 17, 2026, the Company issued 19,434 shares at a price of $2.30 per share to a director in settlement of $44,698 in fees owed related to their consulting and director's agreements. The fair value of the shares was $44,698.

On April 28, 2026. the Company entered into a marketing agreement with a vendor. Under the terms of the agreement, the vendor will assist in video hosting, and distribution services for marketing and communications activities. In connection with the agreement, the Company is to issue the vendor a total of 10,002 common shares in six separate issuances of 1,667 shares each, with the issuance dates being the 28^th day commencing in May 2026 until October 2026. The fair value of the shares issued at May 28, 2026, June 28, 2026, and July 28, 2026, were $22,905, $18,270, and $12,986, respectively, with the fair value per share being determined based off the closing price of the shares at the date of issuance, as the issuance of the shares was contingent upon a service condition leading up to the issuance date. During the three and nine months ended July 31, 2026, a total of $54,161 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.

On May 14, 2026, the Company issued 11,175 shares at a price of $4.00 per share to a director in settlement of $44,700 in fees owed related to their consulting and director's agreements. The fair value of the shares was $44,700.

On May 21, 2026. the Company entered into a marketing agreement with a vendor. Under the terms of the agreement, the vendor will advise the Company regarding media creation, online awareness strategies, and introductions to relevant business contacts and appropriate strategic partners. In connection with the agreement, the Company is to issue the vendor a total of 210,000 common shares in three separate issuances of 70,000 shares each, with the issuance dates being May 22, 2026, June 22, 2026, and July 22, 2026. The fair value of the shares issued at these dates were $945,000, $852,600, and $653,800, respectively, with the fair value per share being determined based off the closing price of the shares at the date of issuance, as the issuance of the shares was contingent upon a service condition leading up to the issuance date. During the three and nine months ended July 31, 2026, a total of $2,451,400 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.

On May 21, 2026. the Company entered into a marketing agreement with a vendor. Under the terms of the agreement, the vendor will provide strategic marketing and communications services designed to increase awareness, visibility, and engagement with respect to the Company's business, initiatives, and overall market presence. In connection with the agreement, the Company is to issue the vendor a total of 30,000 common shares in six separate issuances of 5,000 shares each, issuance dates being the 21^st day of each month commencing in June 2026 until November 2026. The fair value of the shares issued at June 21, 2026, and July 21, 2026, were $66,400 and $46,700, respectively, with the fair value per share being determined based off the closing price of the shares at the date of issuance, as the issuance of the shares was contingent upon a service condition leading up to the issuance date. During the three and nine months ended July 31, 2026, a total of $113,100 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.

On May 21, 2026. the Company entered into a marketing agreement with a vendor. Under the terms of the agreement, the vendor will provide corporate advisory and investor relations services. In connection with the agreement, the Company is to issue the vendor a total of 9,000 common shares in six separate issuances of 1,500 shares each, issuance dates being the 21^st day of each month commencing in June 2026 until November 2026. The fair value of the shares issued at June 21, 2026, and July 21, 2026, were $19,920 and $14,010, respectively, with the fair value per share being determined based off the closing price of the shares at the date of issuance, as the issuance of the shares was contingent upon a service condition leading up to the issuance date. During the three and nine months ended July 31, 2026, a total of $33,930 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.

On May 21, 2026. the Company entered into a marketing agreement with a vendor. Under the terms of the agreement, the vendor will provide digital media and brand awareness, social media management, content creation, and distribution services. In connection with the agreement, the Company is to issue the vendor a total of 30,000 common shares in two separate issuances of 15,000 shares each, with the issuance dates being June 21, 2026, and July 21, 2026. The fair value of the shares issued at June 21, 2026, and July 21, 2026, were $199,200 and $140,010, respectively, with the fair value per share being determined based off the closing price of the shares at the date of issuance, as the issuance of the shares was contingent upon a service condition leading up to the issuance date. During the three and nine months ended July 31, 2026, a total of $339,210 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.

Shares Issued for Conversion of Payables

Between November 30, 2024 and January 31, 2025, the Company issued 207,594 shares of common stock with a fair value of $122,898 to settle outstanding payables. These transactions resulted in a gain on conversion of payables of $43,176.

Warrants

Warrants Issued for Services

On January 21, 2025, the Company issued 82,500 warrants to Director 1 for a fair value of $26,686. The warrants vested immediately. During the three- and nine-months ending July 31, 2025, an expense of $26,686 was incurred and was included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.

On June 5, 2025, the Company granted milestone warrants to three Directors.  The milestones were defined as follows:

Milestone 1 - One quarter of the warrants granted Warrants shall vest upon the Company completing and receiving the results of the three-month Collagen Study in Boston, MA.  Milestone achieved July 8, 2025.

Milestone 2 - Second quarter of the warrants granted shall vest upon the Company listing its shares of common stock in The Nasdaq Stock Market, LLC, or any such other recognized stock exchange in North America.  Milestone achieved May 21, 2026.

Milestone 3 - Third quarter of the warrants granted shall vest upon the Company's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed. Milestone achieved June 17, 2026.

Milestone 4 - Fourth and final quarter if the warrants granted shall vest upon the Company submitting a 510(k) application to the FDA.

On July 8, 2025, the first milestone was achieved, and the Company recorded a total expense of $399,111 within management and directors' salaries and fees on the unaudited condensed interim statements of operations during the year ended October 31, 2025.

On May 21, 2026, the second milestone was achieved, and the Company recorded a total expense of $399,127 within management and directors' salaries and fees on the unaudited condensed interim statements of operations during the three months ending July 31, 2026.

On June 17, 2026, the third milestone was achieved, and the Company recorded a total expense of $399,132 within management and directors' salaries and fees on the unaudited condensed interim statements of operations during the three months ending July 31, 2026.

For the fourth milestone, the Company assessed a greater than 70% probability that this would occur. As of October 31, 2025, the Company anticipated that this would occur on June 30, 2026. As of July 31, 2026, the Company anticipates that this will now occur on March 31, 2027. The expense for the three and nine months ended July 31, 2026, was $46,979 and $139,406, respectively, and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations. During the three and nine months ended July 31, 2025, an expense of $57,309 and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations. See Note 10 - Related Party Transactions for details.

In May 2025, the Company issued 416,667 warrants with a fair value of $102,912 to a consultant for a 24-month consulting agreement. As of October 31, 2025, $78,100 was reported as a prepaid expense on the condensed balance sheet. On May 27, 2026, the Company mutually agreed to terminate, without penalty, the consulting agreement with the consultant, the early termination of this agreement accelerated the prepaid expense of $78,100 in non-cash stock-based compensation to be fully expensed as on the date of the termination. During the three and nine months ended July 31, 2026, a total of $52,445 and $78,100, respectively, was expensed as consulting fees on the unaudited condensed interim statements of operations. During the three and nine months ended July 31, 2025, a total of $11,842, was expensed as consulting fees on the unaudited condensed interim statements of operations.

On December 23, 2025, a Director of the Company, exercised 500,000 milestone warrants for a total amount of proceeds of $500.  The Company issued 500,000 common shares in connection with the warrant exercise.

On May 22, 2026, a Director of the Company, exercised 500,000 milestone warrants for a total amount of proceeds of $500.  The Company issued 500,000 common shares in connection with the warrant exercise.

On May 22, 2026, a former Director of the Company, exercised 400,000 milestone warrants for a total amount of proceeds of $400.  The Company issued 400,000 common shares in connection with the warrant exercise.

On June 8, 2026, a shareholder of the Company, to whom milestone warrants had been transferred, exercised 100,000 milestone warrants for a total amount of proceeds of $100.  The Company issued 100,000 common shares in connection with the warrant exercise.

On June 18, 2026, a former Director of the Company, exercised 250,000 milestone warrants for a total amount of proceeds of $250.  The Company issued 250,000 common shares in connection with the warrant exercise.

The fair value of the warrants issued as compensation during the nine months ended July 31, 2026, and the year ended October 31, 2025, was determined using the following Black-Scholes Pricing model assumptions:

Warrant Incentive Program

On October 1, 2025, the Board of Directors approved a Warrant Exercise Incentive Program (the "Incentive Program"), inviting current warrant holders to exercise their warrants early at the existing exercise price and if they choose to do so, they are then entitled to subscribe for a new full warrant for each warrant exercised, with a purchase price of $0.001, a 36-month expiry date and an exercise price of $2.30.  The initial expiry date of the Incentive Program was December 31, 2025, however, on December 15, 2025, the Board agreed to extend the expiry date of the Incentive Program to April 30, 2026.  On April 28, 2026, the Board agreed to amend an extend further the expiry date of the Incentive Program to June 30, 2026.

On February 11, 2026, under the Company Incentive Program, an initial group of warrant holders exercised 563,573 warrants for a total amount of proceeds of $427,928 and purchased 563,573 new warrants at $0.001 for an additional $564 for the new warrants.  The fair value of the new warrants was calculated as $692,534.

On May 12, 2026, under the Company Incentive Program, a group of warrant holders exercised 4,342,648 warrants for a total amount of proceeds of $1,963,967 and purchased 4,342,648 new warrants at $0.001 for an additional $4,343 for the new warrants.  Of the total warrants exercised, 422,500 warrants were exercised by a company to which one of the Directors of the Company is related and is reported in Note 10 - Related Party Transactions. The fair value of the new warrants was calculated as $11,599,167.

On June 5, 2026, under the Company Incentive Program, a warrant holder exercised 416,667 warrants for a total amount of proceeds of $166,667 and purchased 416,667 new warrants at $0.001 for an additional $417 for the new warrants.  The fair value of the new warrants was calculated as $5,597,073.

On June 18, 2026, under the Company Incentive Program, a warrant holder exercised 202,500 warrants for a total amount of proceeds of $162,000 and purchased 202,500 new warrants at $0.001 for an additional $202 for the new warrants.  The warrant holder is company to which a Director of the Company is related and is reported in Note 10 - Related Party Transactions. The fair value of the new warrants was calculated as $2,328,266.

The fair value of the warrants issued under the incentive program during the nine months ended July 31, 2026, was determined using the following Black-Scholes Pricing model assumptions:

The share price in the model was based on pre-May 21, 2026, the most recent private placement price and post-May 21, 2026, the quoted price in the market, the volatility was based on the historical volatility of comparable public companies, and the expected term is determined using the Simplified Method.

A summary of common stock warrant activity during the nine months ending July 31, 2026, and the year ending October 31, 2025, is as follows:

As of July 31, 2026, there remained an unrecognized stock-based compensation expense for the unvested warrants of $108,257.

Options

On June 7, 2025, the Company approved a Stock Incentive Plan (the "Plan") and Stock-Based Compensation Agreement.  The Plan allows for a maximum of 3,000,000 common shares to be granted under the Plan.

Options Issued for Services

On November 1, 2025, a total of 10,000 stock options were granted to an employee with a total fair value of $17,090, the options will vest 12 months from the grant date, the exercise price is $2.30 per share and will expire on November 1, 2030.  For the three and nine months ended July 31, 2026, the Company recognized under Management and directors' salaries and fees - related parties on the unaudited condensed interim statements of operations related to the value of the options granted and now vested, $4,273 and $12,818, respectively.

On February 9, 2026, a total of 200,000 stock options were granted, in allotments of 50,000 each, to a consultant and three advisors with a total fair value of $302,000.  Twenty-five percent of the options will vest every three months, the exercise price is $2.30 per share, and the expiration date is February 9, 2031.  For the three- and nine-months ending July 31, 2026, the Company recognized under consulting fees on the unaudited condensed interim statements of operations related to the value of the options granted and now vested, $76,121 and $142,312, respectively.

The fair value of the stock options during the nine months ended July 31, 2026, and the year ended October 31, 2025, was determined using the following weighted average Black-Scholes Option Pricing model assumptions:

The stock price in the model was based on the methodology disclosed in Note 3, the volatility was based on the historical volatility of comparable public companies, and the expected term is determined using the Simplified Method.

A summary of common stock options activity during the nine months ended July 31, 2026, and the year ended October 31, 2025, is as follows.

As of July 31, 2026, there remained an unrecognized stock-based compensation expense for the unvested options of $163,995.